Literature DB >> 27824955

Correction: In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer.

Ryohei Miyazaki, Takashi Anayama, Kentaro Hirohashi, Hironobu Okada, Motohiko Kume, Kazumasa Orihashi.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0152665.].

Entities:  

Year:  2016        PMID: 27824955      PMCID: PMC5100983          DOI: 10.1371/journal.pone.0166505

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


There is an error in the third sentence of the seventh paragraph of the Results. The correct sentence is: The ratio showed the best combination of sensitivity and specificity for the prediction of drug sensitivity at values > 72.7% (100 and 93.3% sensitivity and specificity, respectively). There is an error in the last sentence of the seventh paragraph of the Results. The correct sentence is: In the CD-DST, the ROC curve showed that AUC was 0.963 for cell viability (Fig 4b) while the best combination of sensitivity and specificity for prediction of drug sensitivity was at 55.9% (100 and 88.9% sensitivity and specificity, respectively).
Fig 4

ROC curves.

(a) ROC curves for cell viability evaluated using SDI in predicting EFGR mutation showing AUC of 0.958. (b) ROC curves for cell viability evaluated using collagen gel droplet embedded culture drug sensitivity test (CD-DST) in predicting EGFR mutation. AUC was 0.963.

There is an error in Fig 4. Please see the corrected Fig 4 here.

ROC curves.

(a) ROC curves for cell viability evaluated using SDI in predicting EFGR mutation showing AUC of 0.958. (b) ROC curves for cell viability evaluated using collagen gel droplet embedded culture drug sensitivity test (CD-DST) in predicting EGFR mutation. AUC was 0.963.
  1 in total

1.  In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer.

Authors:  Ryohei Miyazaki; Takashi Anayama; Kentaro Hirohashi; Hironobu Okada; Motohiko Kume; Kazumasa Orihashi
Journal:  PLoS One       Date:  2016-04-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.